Company: BIAF
Filing Date: 2025-04-15
Form Type: DRS
Source: 0001641172-25-004915
Chunk: 167

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-15
Form: DRS
Chunk 167
---
 in lieu of the shares of Common Stock that would result in such excess ownership. For each Pre-Funded Warrant sold, the number of shares of Common Stock sold will be reduced on a one-for-one basis. Each share of our Common Stock or Pre-Funded Warrant is being sold together with one April 2025 Warrant to purchase one and one-half share of Common Stock. The shares of Common Stock and/or Pre-Funded Warrants and the accompanying April 2025 Warrants can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. We are also registering the shares of our Common Stock issuable from time to time upon exercise of the Pre-Funded Warrants, April 2025 Warrants and Placement Agent Warrants offered hereby.

Common Stock

The description of our Common Stock under the section “Description of Our Securities—Common Stock” in this prospectus is incorporated herein by reference.

April 2025 Warrants

The following summary of certain terms and provisions of the April 2025 Warrants included with the shares of Common Stock and the Pre-Funded Warrants that are being issued hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the April 2025 Warrants, the form of which will be filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of April 2025 Warrant for a complete description of the terms and conditions of the April 2025 Warrants.

Duration and Exercise Price

Each April 2025 Warrant offered hereby will have an exercise price of $[__] per share(115% of the combined public offering price per share of Common Stock and accompanying April 2025 Warrant) and will be exercisable beginning on the effective date of the Warrant Stockholder Approval, provided however, if the Pricing Conditions are met, the April 2025 Warrants will be exercisable upon issuance (the “Initial Exercise Date”). The April 2025 Warrants will expire on the five-year anniversary of the Initial Exercise Date. The exercise price and number of shares of Common Stock issuable upon exercise of the April 2025 Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our Common Stock and the exercise price, provided however that, in the event of a reverse stock split, the number of shares underlying the April 2025 W